References of "Honore, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDonation after Cardiac Death In Liver Transplantation :is donor age an issue?
Detry, Olivier ULg; De Roover, Arnaud ULg; Squifflet, Jean-Paul ULg et al

in Transplant International (2010, July), 23(Suppl. 1), 415

Detailed reference viewed: 40 (17 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation from donation after cardiac death donors: initial Belgian experience 2003-2007.
Detry, Olivier ULg; Donckier, Vincent; Lucidi, Valerio et al

in Transplant International (2010), 23(6), 611-618

The Belgian experience with donation after cardiac death (DCD) liver transplantation (LT) was retrospectively reviewed, particularly evaluating patient and graft survivals, and biliary complications. From ... [more ▼]

The Belgian experience with donation after cardiac death (DCD) liver transplantation (LT) was retrospectively reviewed, particularly evaluating patient and graft survivals, and biliary complications. From 2003 to 2007, 58 DCD-LT were performed in Belgium. Mean procurement total warm ischemia time was 25 +/- 2 min (mean +/- SEM). Mean cold ischemia time was 451 +/- 18 min. Mean follow-up was 23 +/- 2.2 months. Post-transplant peak aspartate aminotransminases was 2241 +/- 338 UI/l. Patient survivals at 1 month, 1 and 3 years, were 91.3%, 83.3% and 66.9% respectively. Graft survivals at 1 month, 1 and 3 years, were 84.4%, 72.4% and 48.8% respectively. Two patients (3.4%) developed primary nonfunction. Regarding the biliary complications, seven grafts (12%) were lost because of intrahepatic cholangiopathy, and 12 other patients (20.6%) developed bile duct stenoses requiring endoscopic and/or surgical management. The rate of symptomatic ischemic biliary lesions for grafts surviving more than 3 months was 38% (19/50). Although DCD organ donors may be a source of viable liver grafts, results were inferior to those obtained with donation after brain death LT in this series. Prognostic criteria have to be developed to improve results of DCD-LT. [less ▲]

Detailed reference viewed: 53 (18 ULg)
Full Text
Peer Reviewed
See detailDonation after Cardiac Death In Liver Transplantation :is donor age an issue?
Detry, Olivier ULg; De Roover, Arnaud ULg; Squifflet, Jean-Paul ULg et al

in Acta Chirurgica Belgica (2010, April), 110

Detailed reference viewed: 17 (7 ULg)
Full Text
Peer Reviewed
See detailDonation after Cardiac Death In Liver Transplantation :is donor age an issue?
Detry, Olivier ULg; De Roover, Arnaud ULg; Squifflet, Jean-Paul ULg et al

in Acta Gastro-Enterologica Belgica (2010), 35(1), 25

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailEffects of large pore hemofiltration in a swine model of fulminant hepatic failure
Detry, Olivier ULg; Janssen, Nathalie ULg; Cavalier, Etienne ULg et al

in Acta Gastro-Enterologica Belgica (2010), 73(1), 35

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Le lymphangiome kystique du mesentere
Verdin, Vanessa ULg; Seydel, Benoît ULg; Detry, Olivier ULg et al

in Revue Médicale de Liège (2010), 65(11), 615-8

Cystic lymphangioma of the mesentery is a benign condition, probably of malformative origin, and frequently appearing in infancy. Its symptomatology can be very polymorphic. Its diagnosis is suspected by ... [more ▼]

Cystic lymphangioma of the mesentery is a benign condition, probably of malformative origin, and frequently appearing in infancy. Its symptomatology can be very polymorphic. Its diagnosis is suspected by ultrasonography and computed tomography, and definitely confirmed by pathology. About a recent case of cystic lymphangioma of the mesentery diagnosed and operated on at the university hospital of Liege in an adult patient, the authors review its classification and its therapeutic strategy. Surgical resection is indicated in symptomatic cystic lymphangioma. [less ▲]

Detailed reference viewed: 99 (9 ULg)
Full Text
Peer Reviewed
See detailScarless cholecystectomy: laparoscopic surgery by unique umbilical incision
Kohnen, Laurent ULg; Coimbra Marques, Carla ULg; De Roover, Arnaud ULg et al

in Revue Médicale de Liège (2010), 65(10), 543-4

Detailed reference viewed: 48 (1 ULg)
See detailLe ciblage therapeutique: vers une guerre propre et efficace contre le cancer
Castronovo, Vincenzo ULg; Waltregny, David ULg; Detry, Olivier ULg et al

Scientific conference (2009, October)

Detailed reference viewed: 125 (15 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation (LT) from donation after cardiac death (DCD) donors: Multicenter Belgian experience 2003-2007
Detry, Olivier ULg; Donckier, Vincent; Lucidi, Valerio et al

in Transplant International (2009, August), 22(S2), 62-234

Detailed reference viewed: 50 (12 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation from controlled donation after cardiac death (DCD) donors: a single center experience
Detry, Olivier ULg; Veys, Caroline; Seydel, Benoît ULg et al

in Liver Transplantation (2009, July), 15(7), 180-181

Detailed reference viewed: 55 (14 ULg)
Full Text
Peer Reviewed
See detailL’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexavar) :Résultats de l’étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol)
Detry, Olivier ULg; Delwaide, Jean ULg; Deroover, Arnaud ULg et al

in Revue Médicale de Liège (2009), 64(3), 168-170

Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no ... [more ▼]

Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that Sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 months, without any radiologic response or improvement in the delay before symptomatic progression of the disease. The monthly cost of Sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of Sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liège is taking part to a randomized, multicentric study evaluating the use of Sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of Sorafenib with other antitumoral agents. [less ▲]

Detailed reference viewed: 367 (37 ULg)
Full Text
Peer Reviewed
See detailTraitement des carcinomes hépatocellulaires à un stade avancé
Van Daele, Daniel ULg; Belaiche, Jacques ULg; Delwaide, Jean ULg et al

in Revue Médicale de Liège (2009), 64(3), 140-147

Hepatocellular carcinoma is the main primitive tumor of the liver. It occurs in the setting of liver cirrhosis in more than 90% of the cases in developping countries. The prognosis depends on the size ... [more ▼]

Hepatocellular carcinoma is the main primitive tumor of the liver. It occurs in the setting of liver cirrhosis in more than 90% of the cases in developping countries. The prognosis depends on the size, number and extension of the tumor as well as on the severity of the underlying liver disease. The Barcelona Clinic Classification takes into account these different parameters and helps the clinician in the therapeutic decision. Some patients (around 25%) are amenable to therapy with a curative intent (liver transplantation, resection, destruction by radiofrequency). In patients with hepatocellular carcinoma at an intermediate stage, lipiodolized chemoembolization gives a survival advantage in comparison with placebo. No conventional regimen of chemotherapy has a proven survival benefit. In patients with a hepatocellular carcinoma at an advanced stage, sorafenib, an oral multi-targeted kinase inhibitor, is the first coumpound to demonstrate a significant effect on survival free of disease progression in a selected group of patients. Its toxicity profile is particularly favourable. Combination of surgical and medical therapies should be properly evaluated in clinical trials in the near future. [less ▲]

Detailed reference viewed: 217 (9 ULg)
Full Text
Peer Reviewed
See detailLiver transplant donation after cardiac death : experience at the University of Liège
Detry, Olivier ULg; Seydel, Benoît ULg; Delbouille, Marie-Hélène ULg et al

in Transplantation Proceedings (2009), 41(2), 582-4

Aim: Donation after cardiac death (DCD) has been proposed to partly overcome the organ donor shortage. In liver transplantation, the additional warm ischemia linked to DCD procurement may promote higher ... [more ▼]

Aim: Donation after cardiac death (DCD) has been proposed to partly overcome the organ donor shortage. In liver transplantation, the additional warm ischemia linked to DCD procurement may promote higher rate of primary non-function and ischemic type biliary lesions. In this study we reviewed the results of DCD liver transplantation at the University of Liège. Patients and Methods: From 2003 to 2007, 13 controlled DCD liver transplantations were consecutively performed. The records of all donors and recipients were retrospectively reviewed, particularly evaluating the outcome and the occurrence of biliary complications. Mean follow-up was 25 months. Results: Mean donor age was 51 years and their mean intensive care stay was 5.4 days. Mean time between ventilation arrest and cardiac arrest was 9.3 min. Mean time between cardiac arrest and arterial flush was 7.7 min. No touch period was 2 to 5 min. Mean graft cold ischemia was 295 min and mean suture warm ischemia was 38 min. Postoperatively there was no primary non-function. Mean peak transaminase was 2,546 UI/ml. Patient and graft survival was 100% at one year. Two patients (15%) developed graft main bile duct stenosis and underwent endoscopic management. No patient developed symptomatic intrahepatic bile duct strictures or needed retransplantation in the follow-up. Conclusions: The experience of the transplantation department of the University of Liege confirms that controlled DCD donors may be a valuable source of transplantable liver grafts, in case of short procurement warm ischemia and short transplant cold ischemia. [less ▲]

Detailed reference viewed: 138 (22 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Transplantation hépatique pour un hémangio-endothéliome épithélioïde du foie
Tonglet, M.; Delfosse, V.; Detry, Olivier ULg et al

in Revue Médicale de Liège (2009), 64(2), 68-70

L’hémangioendothéliome épithélioïde est une affection maligne rare qui peut survenir dans le foie. Lorsque la forme est multifocale et bilobaire, la transplantation hépatique constitue le traitement ... [more ▼]

L’hémangioendothéliome épithélioïde est une affection maligne rare qui peut survenir dans le foie. Lorsque la forme est multifocale et bilobaire, la transplantation hépatique constitue le traitement curateur de cette affection. Dans cet article, les auteurs décrivent le diagnostic et le traitement d’une femme de 52 ans souffrant d’un hémangioendothéliome épithélioïde hépatique traitée par transplantation du foie. [less ▲]

Detailed reference viewed: 158 (14 ULg)
Full Text
Peer Reviewed
See detailLaparoscopic management of colonoscopic perforations
Bouffioux, Laurent ULg; Coimbra Marques, Carla ULg; Lespagnard, A. C. et al

in Acta Gastro-Enterologica Belgica (2009, January), 72(1), 70

Detailed reference viewed: 77 (24 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation from donation after cardiac death (DCD) donors: Belgian experience 2002-2007
Detry, Olivier ULg; Donckier, Vincent; Lucidi, V. et al

in Acta Gastro-Enterologica Belgica (2009, January), 72(1), 21

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailLe ciblage thérapeutique : vers une guerre propre et efficace contre le cancer
Castronovo, Vincenzo ULg; Waltregny, David ULg; Detry, Olivier ULg et al

in Revue Médicale de Liège (2009), 64

One promising avenue towards the development of more selective, better anticancer drugs consists in the targeted delivery of bioactive compounds to the tumor environment by means of binding molecules ... [more ▼]

One promising avenue towards the development of more selective, better anticancer drugs consists in the targeted delivery of bioactive compounds to the tumor environment by means of binding molecules specific for tumor-associated biomarkers. Eligibility of such markers for therapeutic use implies ideally three criteria : (i) accessibility from the bloodstream, (ii) expression at sufficient level and (iii) no (or much lower) expression in normal tissues. Most current discovery strategies (such as biomarker searching into body fluids) provide no clue as to whether proteins of interest are accessible, in human tissues, to suitable high-affinity ligands, such as systemically delivered monoclonal antibodies. Innovative proteomic technologies are able to identify such accessible biomarkers and represent a key step in the clinical development of such target therapies. [less ▲]

Detailed reference viewed: 144 (35 ULg)
Full Text
Peer Reviewed
See detailSurgical management of hepatic metastases of colorectal origin.
Gilson, Nathalie; Honore, Charles ULg; Detry, Olivier ULg et al

in Acta Gastro-Enterologica Belgica (2009), 72(3), 321-6

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or ... [more ▼]

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or metachronously, liver metastases. Different means such as chemotherapy, targeted therapies, radiofrequency ablation, portal vein embolization and two-stage hepatectomy may be used to make these metastases eventually resectable and to increase overall survival. This is a short review of these different methods used to increase resectability but also on the integration of these parameters in a larger approach of colorectal liver metastasis surgery especially insisting on multidisciplinary discussion. [less ▲]

Detailed reference viewed: 99 (6 ULg)